DE68906309D1 - Methode zur behandlung von kachexie und bestimmte dafuer anzuwendende verbindungen. - Google Patents

Methode zur behandlung von kachexie und bestimmte dafuer anzuwendende verbindungen.

Info

Publication number
DE68906309D1
DE68906309D1 DE8989306147T DE68906309T DE68906309D1 DE 68906309 D1 DE68906309 D1 DE 68906309D1 DE 8989306147 T DE8989306147 T DE 8989306147T DE 68906309 T DE68906309 T DE 68906309T DE 68906309 D1 DE68906309 D1 DE 68906309D1
Authority
DE
Germany
Prior art keywords
hydrogen
alkyl
halogen
specific compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8989306147T
Other languages
English (en)
Other versions
DE68906309T2 (de
Inventor
Yo Takiguchi
Jun Ohsumi
Yasuo Shimoji
Kazuhiko Sasagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of DE68906309D1 publication Critical patent/DE68906309D1/de
Publication of DE68906309T2 publication Critical patent/DE68906309T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE89306147T 1988-06-16 1989-06-16 Methode zur Behandlung von Kachexie und bestimmte dafür anzuwendende Verbindungen. Expired - Fee Related DE68906309T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14913788 1988-06-16

Publications (2)

Publication Number Publication Date
DE68906309D1 true DE68906309D1 (de) 1993-06-09
DE68906309T2 DE68906309T2 (de) 1994-01-05

Family

ID=15468558

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68922408T Expired - Lifetime DE68922408D1 (de) 1988-06-16 1989-06-16 Neue Triazolopyrimidin- und Pyrazolopyrimidinderivate zur Behandlung von Kachexie.
DE89306147T Expired - Fee Related DE68906309T2 (de) 1988-06-16 1989-06-16 Methode zur Behandlung von Kachexie und bestimmte dafür anzuwendende Verbindungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE68922408T Expired - Lifetime DE68922408D1 (de) 1988-06-16 1989-06-16 Neue Triazolopyrimidin- und Pyrazolopyrimidinderivate zur Behandlung von Kachexie.

Country Status (9)

Country Link
US (2) US5055479A (de)
EP (2) EP0508549B1 (de)
JP (1) JPH0276880A (de)
KR (1) KR910000737A (de)
AT (2) ATE88894T1 (de)
CA (1) CA1329199C (de)
DE (2) DE68922408D1 (de)
ES (1) ES2057126T3 (de)
IE (2) IE930392L (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1330079C (en) * 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
JPH10218881A (ja) * 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
JP2002043785A (ja) 2000-07-28 2002-02-08 Murata Mfg Co Ltd シールドケース及びそれを用いた電子機器及びそれを用いた電子装置及びシールドケースの製造方法
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
DK1433480T3 (da) * 2001-07-13 2011-04-11 Btg Internat Ltd Company Lægemiddel indeholdende pyrimidin-derivat
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
JP2005524649A (ja) * 2002-02-25 2005-08-18 カイロン コーポレーション Ｍｃ４−ｒアゴニストの鼻腔内投与
CA2486966A1 (en) * 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
US7051505B2 (en) * 2002-08-21 2006-05-30 Greg Brannstrom Tomato harvester
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7625909B2 (en) * 2003-05-23 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinazolinone compounds
US20050009919A1 (en) * 2003-07-07 2005-01-13 Clouatre Dallas L. Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
KR20060105785A (ko) * 2003-11-19 2006-10-11 카이론 코포레이션 감소된 생체축적을 갖는 퀴나졸리논 화합물
WO2009120836A1 (en) * 2008-03-26 2009-10-01 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
BRPI0911659B8 (pt) 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
GB0917774D0 (en) 2009-10-09 2009-11-25 Senexis Ltd Novel pharmaceutical compounds
GB0917775D0 (en) 2009-10-09 2009-11-25 Btg Int Ltd Novel pharmaceutical compounds
WO2012027239A1 (en) * 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
KR20160101398A (ko) 2015-02-17 2016-08-25 순천대학교 산학협력단 바륨타이타네이트층을 포함하는 복합 세라믹 전극의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51141896A (en) * 1975-05-31 1976-12-07 Sankyo Co Ltd Process for preparing fused ring triazoropyrimidine derivatives
DE2704030A1 (de) * 1976-02-12 1977-08-18 Sandoz Ag Neue organische verbindungen, ihre herstellung und verwendung
JPS5353697A (en) * 1976-10-20 1978-05-16 Sankyo Co Ltd Tricyclic triazolopyrimidine derivatives
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
JPS5735593A (en) * 1980-08-12 1982-02-26 Mochida Pharmaceut Co Ltd Novel pyrolo 3,2-e -s-triazolo 1,5-a pyrimidine derivative
WO1983002944A1 (fr) * 1982-02-19 1983-09-01 Ohnishi, Haruo NOUVEAUX DERIVES DE s-TRIAZOLEAD1,5-aBDPYRIMIDINE
CA1330079C (en) * 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same

Also Published As

Publication number Publication date
EP0347252A2 (de) 1989-12-20
DE68922408D1 (de) 1995-06-01
EP0508549B1 (de) 1995-04-26
EP0508549A3 (de) 1992-11-25
US5055479A (en) 1991-10-08
ES2057126T3 (es) 1994-10-16
EP0347252A3 (de) 1991-03-27
JPH0276880A (ja) 1990-03-16
IE62915B1 (en) 1995-03-08
EP0347252B1 (de) 1993-05-05
EP0508549A2 (de) 1992-10-14
ATE121744T1 (de) 1995-05-15
DE68906309T2 (de) 1994-01-05
US5086057A (en) 1992-02-04
CA1329199C (en) 1994-05-03
IE930392L (en) 1989-12-16
IE891963L (en) 1989-12-16
KR910000737A (ko) 1991-01-30
ATE88894T1 (de) 1993-05-15

Similar Documents

Publication Publication Date Title
DE68906309D1 (de) Methode zur behandlung von kachexie und bestimmte dafuer anzuwendende verbindungen.
HK1039488A1 (en) Tricylic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
ATE139783T1 (de) Azasteroide zur behandlung prostatischer hypertrophie, ihre herstellung und verwendung
DE3783988D1 (de) Zyklische enolderivate, herstellung und anwendung.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
ATE198891T1 (de) Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
ATE92316T1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
SE8304006D0 (sv) Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
TNSN87045A1 (fr) Procede de preparation d'inhibiteurs de l'enzyme de conversion de l'angiotensine
DE3775666D1 (de) Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.
PT84157A (en) Process for preparing heptanoyl-glu-asp-ala-amino acid immunostimmulants
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
NO173991C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2,5-ditiazocin-derivater
RO92245A (ro) Procedeu pentru prepararea unor derivati de 1,6-naftiridina
DE3574675D1 (de) Verfahren zum sterilisieren von rekombinantem mikroorganismus.
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
SE8702697D0 (sv) Method of treating ischaemic vascular diseases
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
DE3788035D1 (de) Etodolac zur Hemmung von Gelenkversteifung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee